Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Autophagy
    (5)
  • EGFR
    (5)
  • Apoptosis
    (3)
  • Antibody-Drug Conjugates (ADCs)
    (2)
  • CDK
    (2)
  • FGFR
    (2)
  • Ferroptosis
    (2)
  • HER
    (2)
  • Histone Methyltransferase
    (2)
  • Others
    (23)
Filter
Search Result
Results for "

advanced cancer

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    67
    TargetMol | Inhibitors_Agonists
  • Compound Libraries
    1
    TargetMol | Compound_Libraries
  • Inhibitory Antibodies
    11
    TargetMol | Inhibitory_Antibodies
  • Natural Products
    3
    TargetMol | Natural_Products
  • Recombinant Protein
    9
    TargetMol | Recombinant_Protein
  • Isotope Products
    2
    TargetMol | Isotope_Products
  • Antibody Products
    1
    TargetMol | Antibody_Products
Aplidine
T9715137219-37-5
Aplidine possesses antiviral activity against SARS-CoV-2(IC90 = 0.88 nM). Aplidine is a potent anti-cancer agent by targeting eukaryotic translation elongation factor 1 Alpha 2(EEF1A2, Kd = 80 nM).
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Valspodar
PSC 833
T17216121584-18-7
Valspodar (PSC 833), a specific P-glycoprotein inhibitor and MDR regulator, is commonly used as a chemical sensitizer in the study of advanced epithelial ovarian cancer.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Avotaciclib
BEY1107, Avotaciclib
T394031983983-41-0In house
Avotaciclib (BEY1107) is a potent, orally active cyclin-dependent kinase 1 (CDK1) inhibitor, suitable for research in locally advanced or metastatic pancreatic cancer.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Camizestrant
Estrogen receptor antagonist 2
T112372222844-89-3In house
Camizestrant (Estrogen receptor antagonist 2) is an antagonist of the estrogen receptor and can be used in studies about ER+ HER2-advanced breast cancer[1].
  • Inquiry Price
6-8 weeks
Size
QTY
Conteltinib
SY-707, CT-707
T149971384860-29-0In house
Conteltinib (CT-707) is an enzyme inhibitor with antitumor activity targeting FAK, ALK, and Pyk2.Conteltinib exhibits significant inhibition of FAK, overcomes hypoxia-mediated sorafenib resistance in hepatocellular carcinoma through inhibition of YAP signaling, and can be used in advanced ALK-positive non-small-cell lung cancer and lymphoma.
  • Inquiry Price
6-8 weeks
Size
QTY
Emitefur
BOF-A2, BOFA2, BOF A2
T27259110690-43-2In house
Emitefur (BOF-A 2) is an orally active and potent 5-fluorouracil derivative with anticancer and antitumor activity.Emitefur is used in advanced gastric cancer, breast cancer and metabolism-related diseases.
  • Inquiry Price
6-8weeks
Size
QTY
Ataquimast
T30190182316-31-0In house
Ataquimast is used in curing advanced receptor-positive breast cancer.
  • Inquiry Price
6-8 weeks
Size
QTY
TargetMol | Inhibitor Sale
Enloplatin
T68065111523-41-2In house
Enloplatin is a carboplatin analog that has a partial role in advanced ovarian cancer.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Lapatinib
GW572016, GSK572016
T0078231277-92-2
Lapatinib (GW572016) is an inhibitor of ErbB2 and EGFR (IC50=9.2 10.8 nM) with oral activity. Lapatinib has antitumor activity and can be used to treat advanced or metastatic breast cancer with HER2 overexpression.
  • Inquiry Price
Size
QTY
Lapatinib ditosylate monohydrate
Lapatinib ditoluenesulfonate monohydrate, Tyverb ditosylate monohydrate, Lapatinib ditosylate monohydrate, Lapatinib ditosilate hydrate, Tykerb ditosylate monohydrate
T0078L388082-78-8
Lapatinib ditosylate (Lapatinib tosilate) monohydrate is a tyrosine kinase receptor inhibitor used in the therapy of advanced breast cancer and other solid tumors. Lapatinib ditosylate monohydrate therapy is associated with transient elevations in serum aminotransferase levels and rare instances of clinically apparent acute liver injury.
  • Inquiry Price
Size
QTY
Abemaciclib
LY2835219, CDK4 6 dual inhibitor
T23811231929-97-7
Abemaciclib (LY2835219) is a dual inhibitor of CDK4 6 (IC50=2 10 nM) with selectivity and specificity. Abemaciclib has antitumor activity and is used to treat advanced or metastatic breast cancer.
  • Inquiry Price
Size
QTY
OB 24 hydrochloride
T41175939825-12-4In house
OB 24 hydrochloride is a potent and selective heme oxygenase 1 (HO-1) inhibitor (IC50 values are 1.9 and >100 μM for HO-1 and HO-2 respectively), reduces protein carbonylation and reactive oxygen species formation in advanced prostate cancer cells (PCA). Inhibits cell proliferationin vitroand PCA tumor growth and lymph node/lung metastasesin vivo. Synergizes with Taxol.
  • Inquiry Price
8-10 weeks
Size
QTY
rabusertib
LY2603618, IC-83
T6084911222-45-2
Rabusertib (IC-83) is an inhibitor of the cell cycle checkpoint kinase 1 (chk1) with potential chemopotentiating activity. Rabusertib has been used in trials studying the treatment of Cancer, Solid Tumors, Advanced Cancer, Pancreatic Neoplasms, and Non-Small Cell Lung Cancer.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Treosulfan
Treosulphan, NSC 39069
T17159299-75-2
Treosulfan (NSC 39069) is a bifunctional alkylating agent used in the treatment of advanced ovarian cancer.[2]
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Samotolisib
GTPL8918, LY3023414
T68831386874-06-1
Samotolisib (LY3023414) is an oral ATP competitive inhibitor of the class I PI3K isoforms, DNA-PK, and mTOR. Samotolisib (LY3023414) has been used in trials studying the treatment of Neoplasm, Solid Tumor, COLON CANCER, BREAST CANCER, and Advanced Cancer, among others.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
AZD-9574
T97562756333-39-6
AZD-9574 is a selective inhibitor of PARP1 at the sites of SSBs. AZD-9574 exhibits anti-cancer activities and can be used in studies about HRD+ breast cancer and advanced solid malignancies.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Durvalumab
MEDI 4736
T111261428935-60-7
Durvalumab (MEDI 4736) is a humanized monoclonal antibody targeting PD-L1. It can block the interaction of PD-L1 with PD-1 and CD80, with IC50 values of 0.1 and 0.04 nM, respectively. Durvalumab is often used in combination with platinum-based compounds for the treatment of non-small cell lung cancer and advanced hepatocellular carcinoma cells.
  • Inquiry Price
Size
QTY
Glufosfamide
Glucosylifosfamide mustard, D 19575
T15390132682-98-5
Glufosfamide is a novel oxazolophosphamide compound with anticancer activity for the study of advanced non-small cell lung cancer.
  • Inquiry Price
6-8 weeks
Size
QTY
NSC745885
T163544219-52-7
NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 is also an effective anti-tumor agent that displays selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 offers possibilities
  • Inquiry Price
6-8 weeks
Size
QTY
LY2090314
T1755603288-22-8
LY2090314, an effective GSK-3α β inhibitor (IC50: 1.5 nM 0.9 nM), may improve the efficacy of platinum-based chemotherapy regimens. LY2090314 has been used in trials studying the treatment of Leukemia, Advanced Cancer, and Pancreatic Cancer.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
KRASG12C IN-13
T2000832409131-50-4
KRASG12C IN-13 (LY3499446), a potent inhibitor of KRAS G12C, shows potential in the study of advanced solid tumors, specifically non-small cell lung cancer and colorectal cancer.
  • Inquiry Price
10-14 weeks
Size
QTY
gsk2636771
GSK-2636771, GSK 2636771
T20731372540-25-4
GSK2636771, an effective, specific, orally bioavailable, PI3Kβ inhibitor, has been used in cancer, lymphoma, solid neoplasm, recurrent solid neoplasm, and advanced malignant neoplasm.
  • Inquiry Price
Size
QTY
Heptaplatin
NSC644591 NSCD644591 SKI2053R,Heptaplatin Sunpla,HTP
T21307146665-77-2
Heptaplatin, a new platinum derivative with anticancer activity, is used against various cancer cell lines, including cisplatin-resistant cancer cell lines. It has been reported to have a response rate of 17% as a single agent, and tolerable toxicity in t
  • Inquiry Price
7-10 days
Size
QTY
Temsirolimus
NSC 683864, CCI-779
T2145162635-04-3
Temsirolimus (CCI-779) is a specific mTOR inhibitor ( IC50: 1.76 μM), used in the treatment of advanced renal cell cancer.
  • Inquiry Price
Size
QTY